Regenerative Medicine Market in the US to grow at a remarkable CAGR of more than 33% By 2020

Regenerative Medicine Market in the US enhances the decision making capabilities & helps to create an effective counter strategies to gain competitive advantage

SUITE 600, DALLAS, TEXAS, UNITED STATES, February 24, 2017 /EINPresswire.com/ -- Orbis Research expect the Regenerative Medicine Market in the US to grow at a remarkable CAGR of more than 33% during the forecast period

Regenerative medicine deals with the process of using therapeutically-induced or laboratory grown human tissue to treat diseased or injured human cells, tissues, or organs. It is an emerging field of treatment that helps in producing new cells to substitute malfunctioning or injured cells as a vehicle to treat disease and injury. The regenerative medicine market can be characterized into three major modalities, namely tissue engineering, biomaterials/ biomolecules, and stem cell therapy.

Get a PDF Sample of Regenerative Medicine Market in the US Report at:
http://www.orbisresearch.com/contacts/request-sample/201876

Regenerative Medicine Market in the US to grow at a fast pace, because of the growing demand for tissue-engineered and stem cell products for the treatment of various diseases. The potential of these medicines in regenerating diseased organs is one of the major factors that drives the market in the US. The stem cells application and advancements in nanotechnology will further drive the progress in this market.

Segmentation by product and analysis of - cell therapy and scaffold

Cell therapy helps in treating the diseases or to improving the functioning of the existing cells, by administrating of cells into the body. This therapy addresses medical conditions related to the bone, cartilage, heart, skin, digestive system, reproductive system, eye, blood, spine, brain, and the nervous system. In 2015, cell therapy segment accounted for approximately 80% of the market share.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -
Cell therapy
Scaffold

Place a Purchase Order for this Report at:
http://www.orbisresearch.com/contact/purchase/201876

Segmentation by application and analysis of - dermatology, musculoskeletal, ocular, and cardiovascular
The year 2015 saw the precedence of the dermatology segment, accounting for a market share of more than 51%. Dermatology includes the treatment of burns and chronic wounds that requires a quick response, and skin grafting is essential in many cases. Factors such as the

increase in obesity and diabetes, growing elderly population, and an increase in life expectancy are some of the causes contributing to the growth of the dermatology market.
The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -
Dermatology
Musculoskeletal
Ocular
Cardiovascular
Regenerative medicine market in the US is highly competitive and fragmented because of the presence of several established vendors and this competitive environment is expected to intensify with advances in R&D and technological innovations. International players are likely to acquire regional or local players to enhance their products and expand their market share during the forecast period.

The top vendors in the market are -
Acelity
Mesoblast
Organogenesis
Reprocell
Stryker

Other prominent vendors include Aastrom Biosciences, Acologix, AlloCure, Allosource, Alphatec Spine, Altrika, Amorcyte, Argos Therapeutics, Athersys, Avita Medical, Axogen, Bacterin International, Baxter, Bellicum Pharmaceuticals, BioCardia, BioLife Solutions, BioRestorative Therapies, BioTissue Technologies, Bluebird Bio, BrainStorm Cell Therapeutics, Calimmune, Capricor, Celyad (Cardio3 BioSciences), Cell Medica, Cesca, CryoLife, Cynata Therapeutics, Cytori, Cytori Therapeutics, Dendreon, DiscGenics, Fate Therapeutics, Fibrocell, Fibrocell Science, Forticell Bioscience, Fortress Biotech, Gamida Cell, Geron, Harvard Apparatus Regenerative Technology, Healthpoint, Histogen, Histogenics, Humacyte, Immunocellular Therapeutics P, Integra Life Sciences, Intercytex, InVivo Therapeutics, iSTO Technologies, Juventas Therapeutics, Kensey Nash, Kiadis Pharma, Kinetic Concept, Living Cell Technologies, MaxCyte, Medtronics, Mesoblast, MiMedix Group, Nanofiber Solutions CTO, Nanotope, Neuralstem, Newlink Genetics, Northwest Biotherapeutics, NovaRx, Ocata Therapeutics, Opexa , Therapeutics, Organovo Holdings, Orteq, Orthofix, Osiris Therapeutics, Osteotech, Pfizer, Pluristem Therapeutics, Prima BioMed, Q Therapeutics, RhinoCyte, RTI Surgical, SanBio, Sangamo, Shire Regenerative Medicine, StemCells, Stratatech, TEI Biosciences, Tengion, Thermo Fischer Scientific, TiGenix, Tissue Genesis, TissueGene, VentriNova, Vericel, ViaCyte, Vistagen, and Zimmer.

Key questions answered in the report include
What will the market size and the growth rate be in 2020?
What are the key factors driving the regenerative medicine market in the US?
What are the key market trends impacting the growth of the regenerative medicine market in the US?
What are the challenges to market growth?
Who are the key vendors in the regenerative medicine market in the US?
What are the market opportunities and threats faced by the vendors in the regenerative medicine market in the US?
What are the key outcomes of the five forces analysis of the regenerative medicine market in the US?

Companies Mentioned:

Acelity, Mesoblast, Organogenesis, Reprocell, Stryker, Aastrom Biosciences, Acologix, AlloCure, Allosource, Alphatec Spine, Altrika, Amorcyte, Argos Therapeutics, Athersys, Avita Medical, Axogen, Bacterin International, Baxter, Bellicum Pharmaceuticals, BioCardia, BioLife Solutions, BioRestorative Therapies, BioTissue Technologies, Bluebird Bio, BrainStorm Cell Therapeutics,

Calimmune, Capricor, Celyad (Cardio3 BioSciences), Cell Medica, Cesca, CryoLife, Cynata Therapeutics, Cytori, Cytori Therapeutics, Dendreon, DiscGenics, Fate Therapeutics, Fibrocell, Fibrocell Science, Forticell Bioscience, Fortress Biotech, Gamida Cell, Geron, Harvard Apparatus Regenerative Technology, Healthpoint, Histogen, Histogenics, Humacyte, Immunocellular Therapeutics P, Integra Life Sciences, Intercytex, InVivo Therapeutics, iSTO Technologies, Juventas Therapeutics, Kensey Nash, Kiadis Pharma, Kinetic Concept, Living Cell Technologies, MaxCyte, Medtronics, Mesoblast, MiMedix Group, Nanofiber Solutions CTO, Nanotope, Neuralstem, Newlink Genetics, Northwest Biotherapeutics, NovaRx, Ocata Therapeutics, Opexa , Therapeutics, Organovo Holdings, Orteq, Orthofix, Osiris Therapeutics, Osteotech, Pfizer, Pluristem Therapeutics, Prima BioMed, Q Therapeutics, RhinoCyte, RTI Surgical, SanBio, Sangamo, Shire Regenerative Medicine, StemCells, Stratatech, TEI Biosciences, Tengion, Thermo Fischer Scientific, TiGenix, Tissue Genesis, TissueGene, VentriNova, Vericel, ViaCyte, Vistagen, and Zimmer.

Hector Costello
Orbis Research
+1 (214) 884-6817
email us here
